• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • HER2-mutant NSCLC
Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope
Posted innews Oncology Respiratory

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

Posted by By MedXY 10/25/2025
This article reviews recent clinical trial data showing sevabertinib's efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.
Read More
Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Posted innews Oncology Specialties

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

Posted by By MedXY 08/01/2025
Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.
Read More
  • Prior Osteotomy Lowers Implant Survival and Raises TKA Complexity — but Early Pain and Function Are Similar: Insights from 189,932 Dutch Arthroplasties
  • Wearables and Behaviour Change Work Best: Physical Activity Interventions After Hip and Knee Arthroplasty Improve Steps but Not Sedentary Time
  • Valgus Bracing Lowers Medial Tibiofemoral Cartilage Pressure and Shifts Load Laterally in Varus Knee Osteoarthritis
  • T2 Mapping Detects BMI-Linked Cartilage Changes and Lateral Compartment Signal Differences in Population-Based Knee OA
  • Partitioning Knee Osteoarthritis Genetic Risk by BMI Association Clarifies Prediction and Mechanisms
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial depression diabetes diet epidemiology exercise gut microbiota health heart failure Hypertension immunotherapy inflammation long-term outcomes MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial sexual health targeted therapy treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in